Gilead Sciences, Inc. vs Mongodb Inc — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Mongodb Inc trades at $435.46 (market cap $33.51B). The key difference: Gilead Sciences, Inc. is far larger — about 4.9× Mongodb Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| GILD | MDB | |
|---|---|---|
Market Cap | $164.99B | $33.51B |
Sector | Health | Technology |
52-Week High | $155.80 | $440.25 |
52-Week Low | $110.56 | $204.37 |
Enterprise Value | $188.06B | $31.12B |
Dividend Yield | 2.47% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →